Table 3.
Clinical Characteristics
| Characteristic | Chlorpromazine, n (%) | Olanzapine, n (%) |
|---|---|---|
| Primary diagnosis | ||
| Neurodevelopmental disorders | 9 (12.5) | 9 (12.3) |
| Psychotic disorders | 10 (13.9) | 19 (26.0) |
| Disruptive, impulse-control, and conduct disorders | 20 (27.8) | 9 (12.3) |
| Mood disorders | 33 (45.8) | 36 (49.3) |
| Coadministered IM medication | ||
| Diphenhydramine* | 26 (36.1) | 52 (71.2) |
| Benzodiazepine | 1 (1.4) | 0 (0) |
| Diphenhydramine + benzodiazepine | 1 (1.4) | 1 (1.4) |
| Scheduled oral antipsychotic, yes | 23 (32) | 25 (34) |
| Oral antipsychotic | ||
| Chlorpromazine | 5 (6.9) | 0 (0) |
| Olanzapine | 1 (1.4) | 10 (13.7) |
| Risperidone | 5 (6.9) | 4 (5.5) |
| Quetiapine | 4 (5.6) | 1 (1.4) |
| Aripiprazole | 3 (4.2) | 5 (6.9) |
| Ziprasidone | 2 (2.8) | 1 (1.4) |
| Lurasidone | 1 (1.4) | 2 (2.7) |
| Haloperidol + quetiapine | 1 (1.4) | 1 (1.4) |
| Aripiprazole + lurasidone | 1 (1.4) | 1 (1.4) |
| Within 6 hr of next IM | 6 (8.3) | 1 (1.4) |
* p < 0.001.